CHROMADEX CORP (CDXC)
US1710774076 - Common Stock
CDXC gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. CDXC has an excellent financial health rating, but there are some minor concerns on its profitability. CDXC is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
CDXC had positive earnings in the past year.
CDXC had a positive operating cash flow in the past year.
CDXC had negative earnings in each of the past 5 years.
In the past 5 years CDXC reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.63%, CDXC is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
CDXC has a Return On Equity of 4.32%. This is in the better half of the industry: CDXC outperforms 72.73% of its industry peers.
CDXC has a better Return On Invested Capital (0.91%) than 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.32% | ||
| ROIC | 0.91% |
ROA(3y)-28.83%
ROA(5y)-43.66%
ROE(3y)-53.52%
ROE(5y)-87.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CDXC's Profit Margin of 1.62% is fine compared to the rest of the industry. CDXC outperforms 67.27% of its industry peers.
The Operating Margin of CDXC (0.49%) is better than 63.64% of its industry peers.
CDXC has a Gross Margin of 61.45%. This is amongst the best in the industry. CDXC outperforms 87.27% of its industry peers.
CDXC's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.49% | ||
| PM (TTM) | 1.62% | ||
| GM | 61.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.69%
GM growth 5Y3.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CDXC is destroying value.
The number of shares outstanding for CDXC has been increased compared to 1 year ago.
Compared to 5 years ago, CDXC has more shares outstanding
Compared to 1 year ago, CDXC has an improved debt to assets ratio.
2.2 Solvency
CDXC has an Altman-Z score of 13.09. This indicates that CDXC is financially healthy and has little risk of bankruptcy at the moment.
CDXC has a Altman-Z score of 13.09. This is amongst the best in the industry. CDXC outperforms 98.18% of its industry peers.
CDXC has a debt to FCF ratio of 0.00. This is a very positive value and a sign of high solvency as it would only need 0.00 years to pay back of all of its debts.
CDXC has a Debt to FCF ratio of 0.00. This is amongst the best in the industry. CDXC outperforms 94.55% of its industry peers.
CDXC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
CDXC has a Debt to Equity ratio of 0.00. This is in the better half of the industry: CDXC outperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 13.09 |
ROIC/WACC0.08
WACC11.28%
2.3 Liquidity
A Current Ratio of 2.95 indicates that CDXC has no problem at all paying its short term obligations.
With a Current ratio value of 2.95, CDXC perfoms like the industry average, outperforming 50.91% of the companies in the same industry.
CDXC has a Quick Ratio of 2.35. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
CDXC has a Quick ratio (2.35) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 111.11% over the past year.
The Revenue has grown by 9.94% in the past year. This is quite good.
The Revenue has been growing by 21.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)9.94%
Revenue growth 3Y12.14%
Revenue growth 5Y21.5%
Sales Q2Q%31.21%
3.2 Future
CDXC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.82% yearly.
Based on estimates for the next years, CDXC will show a quite strong growth in Revenue. The Revenue will grow by 17.67% on average per year.
EPS Next Y158.29%
EPS Next 2Y93.61%
EPS Next 3Y64.82%
EPS Next 5YN/A
Revenue Next Year16.58%
Revenue Next 2Y18.63%
Revenue Next 3Y17.67%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CDXC is valuated quite expensively with a Price/Earnings ratio of 744.00.
CDXC's Price/Earnings ratio is in line with the industry average.
The average S&P500 Price/Earnings ratio is at 29.20. CDXC is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 60.78, the valuation of CDXC can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CDXC is on the same level as its industry peers.
CDXC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 744 | ||
| Fwd PE | 60.78 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as CDXC.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CDXC is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 139.93 | ||
| EV/EBITDA | 415.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as CDXC's earnings are expected to grow with 64.82% in the coming years.
PEG (NY)4.7
PEG (5Y)N/A
EPS Next 2Y93.61%
EPS Next 3Y64.82%
5. Dividend
5.1 Amount
CDXC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHROMADEX CORP
NASDAQ:CDXC (11/22/2024, 8:00:02 PM)
After market: 7.2601 -0.18 (-2.42%)7.44
-0.19 (-2.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap568.27M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 744 | ||
| Fwd PE | 60.78 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)4.7
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.63% | ||
| ROE | 4.32% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 0.49% | ||
| PM (TTM) | 1.62% | ||
| GM | 61.45% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.95 | ||
| Quick Ratio | 2.35 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y158.29%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.94%
Revenue growth 3Y12.14%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y